Related Experiment Video
Updated: Jun 29, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Balancing efficacy and safety of complement inhibitors
Kanako Watanabe-Kusunoki1, Hans-Joachim Anders2
1Renal Division, Department of Medicine IV, Ludwig-Maximilians (LMU) University Hospital, LMU Munich, Germany; Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Insights
Complement inhibitors offer new treatments for immune diseases like glomerulonephritis. Careful target selection is crucial to balance treatment efficacy with the risk of serious infections, especially in chronic conditions.
Area of Science:
- Immunology
- Nephrology
- Pharmacology
Background:
- Complement inhibitors are emerging as a transformative treatment for immune-mediated diseases, particularly glomerulonephritis.
- The complement system's hierarchical structure presents multiple therapeutic targets.
- However, complement inhibition carries a risk of infectious complications due to its role in host defense.
Purpose of the Study:
- To analyze the complement system's hierarchy and its therapeutic targets.
- To evaluate how targeting proximal vs. distal or selective vs. unselective complement components impacts treatment efficacy and safety.
- To propose patient stratification strategies for optimizing complement inhibitor therapy.
Main Methods:
- Review of the complement system's hierarchical organization.
- Analysis of therapeutic intervention strategies targeting different complement components.
- Consideration of disease characteristics and patient factors in treatment selection.
Main Results:
- Interfering with proximal vs. distal complement targets influences efficacy and safety outcomes.
- Selective vs. unselective inhibition strategies have distinct risk-benefit profiles.
- Patient stratification based on disease activity and immunocompetence is essential.
Conclusions:
- Targeting the complement system holds significant therapeutic promise for glomerulonephritis and other immune diseases.
- Balancing efficacy and safety is paramount, especially for long-term complement blockade in chronic conditions.
- Personalized therapeutic strategies, considering disease type and patient status, are key to successful complement inhibition.
Abstract:
Complement inhibitors have been approved for several immune-mediated diseases and they are considered the next paradigm-shifting approach in the treatment of glomerulonephritis. The hierarchical organization of the complement system offers numerous molecular targets for therapeutic intervention. However, complement is an integral element of host defense and therefore complement inhibition can be associated with serious infectious complications. Here we give a closer look to the hierarchical complement system and how interfering with proximal versus distal or selective versus unselective molecular targets could determine efficacy and safety. Furthermore, we propose to consider the type of disease, immunological activity, and patient immunocompetence when stratifying patients, e.g., proximal/unselective targets for highly active and potentially fatal diseases while distal and selective targets may suit more chronic disease conditions with low or moderate disease activity requiring persistent complement blockade in patients with concomitant immunodeficiency. Certainly, there exists substantial promise for anti-complement therapeutics. However, balancing efficacy and safety will be key to establish powerful treatment effects with minimal adverse events, especially when complement blockade is continued over longer periods of time in chronic disorders.
Related Concept Videos
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:22Dose-Response Relationship: Potency and Efficacy